Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
NCT04640025Phase 2Terminated
- Sponsor
- Incyte
- Start
- Mar 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of itacitinib in myelofibrosis (MF), Bronchiolitis Obliterans (BO), chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Started Mar 2021; status: terminated.
02
Drugs
itacitinib
03
Conditions
myelofibrosis (MF)Bronchiolitis Obliterans (BO)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04640025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640025.